Taller Informativo - HORIZONTE 2020
Financiación europea en Salud e Infraestructuras

Bellaterra, 18 de febrero de 2020

Oportunidades de financiación europea en Salud (H2020, IMI2). Consejos prácticos para la redacción de propuestas

Juan E. Riese PhD MBA
Punto Nacional de Contacto – Reto Social 1 H2020 & IMI2
Experto Nacional en el Comité de Programa del Reto Social 1
Oficina de Proyectos Europeos – SGPIIRI ISCIII

MINISTERIO DE CIENCIA E INNOVACIÓN

Instituto de Salud Carlos III

UAB Universitat Autònoma de Barcelona



H2020: Oportunidades de financiación de proyectos de I+i

- Convocatoria 2020 del Reto Social 1
- Convocatoria 20 de la Iniciativa de Medicamentos Innovadores

Consejos prácticos para la redacción de propuestas



H2020: Oportunidades de financiación de proyectos de I+i

- Convocatoria 2020 del Reto Social 1
- Convocatoria 20 de la Iniciativa de Medicamentos Innovadores

Consejos prácticos para la redacción de propuestas

8 prioridades repartidas en 3 áreas

(I) Better health and care, economic growth and sustainable health systems (Topics BHC)

1. Personalised medicine
2. Innovative health and care industry
3. Infectious diseases and improving global health
4. Innovative health and care systems – Integration of care
5. Decoding the role of the environment for health and well-being
6. Contribution to the Call on Digital Transformation in Health and Care

(II) Digital transformation in health and care (Topics DTH)

(III) Trusted digital solutions and cybersecurity in health and care (Topics TDS)

Otras acciones se encuentran en el programa piloto European Innovation Council: premios, Instrumento PYME, FTI, FET Open

Fuente: Comisión Europea.

(I) Better health and care, economic growth and sustainable health systems

(Topics BHC)

1. Personalised medicine
2. Innovative health and care industry
3. Infectious diseases and improving global health
4. Innovative health and care systems – Integration of care
5. Decoding the role of the environment for health and well-being
6. Contribution to the Call on Digital transformation in Health and Care

H2020

Horizon Europe

Call Identifier: SC1-BHC-06-2020

Name: Digital diagnostics – developing tools for supporting clinical decisions by integrating various diagnostic data

Scope:

- Proposals should develop tools, platforms or services that will use information provided by most relevant diagnostic means for a particular area.
- The solutions should integrate various data sources such as medical records, in vitro and/or in vivo diagnostics, medical imaging, -omics data, functional tests (lab-on-a-chip), etc.
- They should be tested and validated in real-life settings in pilot centers.
- Any medical data relevant for a particular disease may be considered.
- Ethical and legal concerns.

Total Budget: 40 M€

Contribution per project: 8 – 15 M€

Opening date: 4 July 2019

Deadline: 7 April 2020

Type of Action: Research and Innovation (RIA)

Fuente: Comisión Europea.

Call Identifier: SC1-BHC-11-2020

Name: Advancing the safety assessment of chemicals without the use of animal testing

Scope:

- Proposals should consider integrative approaches that build on advances in all relevant fields of science and technology, including elements such as novel *in vitro* and *in silico* tools and the understanding of human biology and related toxicity pathways.
- Also should consider the involvement of the European Commission's Joint Research Centre, any relevant complementary initiatives or any regulatory bodies.

Expected Impact:

- Scientifically sound, practicably implementable non-animal solutions readily deployable to aid in meaningful safety assessment of chemicals.
- Recognition from regulatory bodies and their engagement to translate results, methods and solutions into safety assessment practice.

Total Budget: 60 M€

Contribution per project: 10 – 20 M€

Opening date: 4 July 2019

Deadline: 7 April 2020

Type of Action: Research and Innovation (RIA)

Fuente: Comisión Europea.

Call Identifier: SC1-BHC-17-2020

Name: Global Alliance for Chronic Diseases (GACD) - Prevention and/or early diagnosis of cancer

Scope:

- GACD will focus on early diagnosis of cancer in Low and Middles-Income Countries (LMIC) and/or in vulnerable populations in High-Income Countries (HIC).
- Proposals should then focus on implementation research for the prevention and/or early diagnosis of cancer, derived from existing knowledge about effective and/or promising interventions.
- Also should include a strategy to test the proposed model of intervention and to address the socioeconomic and contextual factors of relevance to the targeted region and community.

Total Budget: 20 M€

Contribution per project: 1 – 3 M€

Opening date: 4 July 2019

Deadline: 7 April 2020

Type of Action: Research and Innovation (RIA)

Fuente: Comisión Europea.

Call Identifier: SC1-BHC-20A-2020

Name: Pre-commercial procurement (PCP) for integrated care solutions

Scope:

- PCP actions target to modernize public services including personal-health and self-care solutions, professional care solutions and ICT-based solutions, as well as all areas of public sector interest.
- Proposals should demonstrate sustainability of the action beyond the life of the project.

Expected impact:

- Reduced fragmentation of demand for innovative solutions in the area of integrated care.
- Increased opportunities for wide market uptake and economies of scale for the supply side.

Total Budget: 25 M€

Contribution per project: 5 – 6 M€

Opening date: 4 July 2019

Deadline: 7 April 2020

Type of Action: Pre-Commercial Procurement

Fuente: Comisión Europea.

Call Identifier: SC1-BHC-20B-2020

Name: Public procurement of innovative solutions (PPI) for diagnostics for infectious diseases

Scope:

- This topic contributes to the EU One Health Action Plan on Antimicrobial Resistance, with the potential implementation of rapid diagnostic tools for infectious diseases in clinical practice.

Expected Impact:

- Implementation of innovative procurement practices for diagnostics for infectious diseases in the EU, based on the most economically advantageous tendering approach.
- Contribute to the European Plan in relation to Better Prevention and Control of AMR and the goal to address patient safety in hospital environments.

Total Budget: shared with BHC-20A

Contribution per project: 3 – 5 M€

Opening date: 4 July 2019

Deadline: 7 April 2020

Type of Action: Public Procurement of Innovative Solutions

Fuente: Comisión Europea.

Call Identifier: SC1-BHC-33-2020

Name: Addressing low vaccine uptake

Scope:

- Proposals should work to increase understanding of the determinants of low vaccine uptake in specific contexts situated in the EU and/or Associated Countries (AC), and develop strategies to increase vaccination rates of essential vaccines within these contexts.
- The approach taken should include a detailed examination of the causes, and the design and testing of one or more interventions to improve vaccine uptake.

Expected Impact:

- Develop practical and readily implementable guidelines.
- Contribute to increasing vaccine coverage in Europe.

Total Budget: 9 M€

Contribution per project: 2 – 3 M€

Opening date: 4 July 2019

Deadline: 7 April 2020

Type of Action: Research and Innovation (RIA)

Fuente: Comisión Europea.

Call Identifier: SC1-BHC-34-2020

Name: New approaches for clinical management and prevention of resistant bacterial infections in high prevalence settings

Scope:

- Proposals should focus on the identification of best practices, and the development and validation of interventions, infection prevention and clinical management plans for dealing with resistant bacterial infections in high prevalence settings.

Expected Impact:

- Availability of tested cost effective models for prevention and treatment of bacterial infections in health care settings.
- Reduced spread of resistant hospital acquired infections in these settings.
- Knowledge that can be of use for other countries, benefitting their local population and diminishing the global spread of resistant bacteria.

Total Budget: 25 M€

Contribution per project: 10 - 15 M€

Opening date: 4 July 2019

Deadline: 7 April 2020

Type of Action: Research and Innovation (RIA)

Fuente: Comisión Europea.

Call Identifier: SC1-BHC-35-2020

Name: Creation of a European wide sustainable network for harmonised large-scale clinical research studies for infectious diseases

Scope:

- Proposals should set a multidisciplinary network able to provide a platform for a rapid response in the conduct of clinical studies in relation to any severe infection.
- They should build on established structures for infectious disease clinical research at national or regional scales.
- It is expected to perform clinical studies and further advance clinical research in the field of infectious diseases.

Expected Impact:

- Reduced cost and time through efficiently implemented clinical trials.
- Create and strengthen the operational capacity and the infrastructures for providing real-time evidence for optimal medical intervention.

Total Budget: 30 M€

Contribution per project: 25 – 30 M€

Opening date: 4 July 2019

Deadline: 7 April 2020

Type of Action: Research and Innovation (RIA)

Fuente: Comisión Europea.

Call Identifier: **SC1-BHC-37-2020**

Name: Towards the new generation of clinical trials – trials methodology research

Scope:

- Proposals should focus on methodology research and develop innovative solutions to improve the design, conduct and analysis of clinical trials.
- Also, it should identify and validate methods that will improve the generalizability of evidence generated through different trials.
- Applicants should identify best practices to prevent bottlenecks in execution of clinical trial, including issues related to patient recruitment.
- In this topic, the European Medicines Agency (EMA) will support the selected applicant consortium in the implementation of the action.

Expected Impact:

- Improved relevance, quality and efficiency of clinical trials conducted with public funding.
- Potential to establish a novel clinical trial methodology supported by regulatory authorities.

Total Budget: 6 M€

Contribution per project: 4 – 6 M€

Opening date: 4 July 2019

Deadline: 7 April 2020

Type of Action: RIA **Lump Sump**

Fuente: Comisión Europea.

Call Identifier: **SC1-BHC-36-2020**

Name: Micro- and nano-plastics in our environment: Understanding exposures and impacts on human health

Scope:

- Proposals should use innovative approaches to provide policy relevant scientific data in support of improved human health hazard and risk assessment of micro- and/or nano-plastics.
- The following research priorities concerning plastics can be considered:

- Environmental/food/water sources and transmission to humans.
- Methods for identification and quantification in foods, environmental media and tissues.
- Exposure levels of humans for biomonitoring.
- Analytical methods for detection.
- Microbial colonization/vectors for pathogens.
- Plastics as condensation nuclei for airborne particulate matter and chemicals harmful to health.
- Toxicology and uptake of additives/adsorbed contaminants.
- Fate of plastics in the gastro-intestinal or respiratory tracts and secondary organs.
- Immune responses.

Total Budget: 25 M€

Contribution per project: 4 – 6 M€

Opening date: 4 July 2019

Deadline: 7 April 2020

Type of Action: Research and Innovation (RIA)

Fuente: Comisión Europea.

Call Identifier: SC1-DTH-12-2020

Name: Use of Real-World Data to advance research on the management of complex chronic conditions

Scope:

- The topic will support clinical research integrating Real World Data from clinical practice or from patient's daily life and linking them with data collected with a research purpose if relevant.
- The focus will be on the use of real world data, either newly acquired or from existing sources (such as data from clinical professional societies/associations, cohorts, registers, biobanks or collected through genome research initiatives) to improve the clinical management of adults with complex chromic conditions. The use of new technologies for data analytics and interpretation such as artificial intelligence and computer modelling are encouraged.

Total Budget: 41 M€

Contribution per project: 4 – 6 M€

Opening date: 4 July 2019

Deadline: 7 April 2020

Type of Action: Research and Innovation (RIA)

Fuente: Comisión Europea.

Prioridad	Topics en esquema Acciones de Coordinación y Apoyo (CSAs) **Fecha de cierre: 07.04.2020**	Mio. €	Nº	Mio. €
Personalised medicine	SC1-HCO-01-2018/19/20: Actions in support of the International Consortium for Personalised Medicine.	1.5-2	2	4
	SC1-HCO-03-2020: Bridging the divide in health research and innovation – boosting return on investment.	1.5-2	1	2
	SC1-HCO-14-2020: ERA-Net: Sustained collaboration of national and regional programmes in cancer research.	Min. 5	1	5
	SC1-HCO-16-2020: ERA-Net: Sustained collaboration of national and regional programmes in research on brain-related diseases and disorders of the nervous system.	Min. 5	1	5
	SC1-HCO-17-2020: Coordinating and supporting research on the human microbiome in Europe and beyond.	1.5-2	1	2
	SC1-HCO-18-2020: Developing methodological approaches for improved clinical investigation and evaluation of high-risk medical devices.	1 -2	1	2
	SC1-HCO-19-2020: Reliable and accessible information on cell and gene-based therapies.	1.5-2	1	2
Infectious diseases and improving global health	SC1-HCO-07-2020: ERA-NET to support the Joint Programming Initiative on Antimicrobial resistance (JPIAMR).	Min. 5	1	5
Innovative health and care systems – Integration of care	SC1-HCO-20-2020: Coordination of clinical research activities of the European Reference Networks.	1.5-2	1	2

Fuente: Comisión Europea.

Prioridad	Topics en esquema Acciones de Coordinación y Apoyo (CSAs)	 Mio €	 Nº	 Mio. €
Contribution to the Call on Digital transformation in Health and Care	SC1-HCC-10-2020: Towards a Health research and innovation Cloud: Capitalising on data sharing initiatives in health research.	2-3	1	3

Fecha de cierre: 07.04.2020

Fuente: Comisión Europea.

(II) Digital transformation in health and care (Topics DTH)

H2020

Horizon Europe

GOBIERNO DE ESPAÑA
MINISTERIO DE CIENCIA E INNOVACIÓN
Instituto de Salud Carlos III

Call Identifier: SC1-DTH-02-2020

Name: Personalized early risk prediction, prevention and intervention based on Artificial Intelligence and Big Data technologies

Digital transformation in Health and Care

Scope:

- Personalized early risk prediction models, estimating the probability that a specific event occurs in a given individual over a predefined time, can enable earlier and better intervention.
- Proposals should build on results of projects and the state of the art in ICT for early risk prediction and introduce innovative ICT solutions through data / data analytics.
- Also should build on the use of already existing and/or new data generated by individuals, health professionals and other service providers (IoT enabled devices, wearables, mobile devices, data source networks or data lakes), with a view to developing personalized early risk prediction, prevention and intervention approaches that meet the needs of individuals while providing them with adequate information to support informed decision making.

Total Budget: 32 M€

Contribution per project: 4 – 6 M€

Opening date: 19 November 2019

Deadline: 22 April 2020

Type of Action: Research and Innovation (RIA)

Fuente: Comisión Europea.

Call Identifier: SC1-DTH-04-2020

Name: International cooperation in smart living environments for ageing people

Digital transformation in Health and Care

Scope:

- Proposals should develop and validate new solutions leading to smart living environments for ageing people, supporting independent active and healthy lifestyles.
- Also should provide personalized advice, guidance and follow-up for key age and health related issues in daily life which impact the person's ability to remain active, healthy and independent.
- They should be based on trans-disciplinary research, involving behavioral, sociological, psychological, medical and other relevant disciplines, including gender and cultural aspects.
- The proposed R&I actions should address either a collaboration **with Japan or with Canada**.

Total Budget: 8 M€

Contribution per project: 4 M€

Opening date: 19 November 2019

Deadline: 22 April 2020

Type of Action: Research and Innovation (RIA)

Fuente: Comisión Europea.

Call Identifier: SC1-DTH-06-2020

Name: Accelerating the uptake of computer simulations for testing medicines and medical devices

Scope:

- Proposals will develop innovative scientific and technological computer modelling solutions for testing medicines and/or medical devices.
- Proposed computer modelling solutions will be the result of a multidisciplinary effort (e.g. within the fields of computational modelling, chemo/bio-informatics, systems biology, pharmacology, -omics (genomics, epigenomics, metabolomics), tissue mechanics, biology, pharmaceutics, medicine, physiology, toxicology, social science aspects such as gender) and must also explore and inform of the reasons for failure should the drug or medical device be found not efficient or safe and will suggest improvements.

Total Budget: 32 M€

Contribution per project: 6 – 8 M€

Opening date: 19 November 2019

Deadline: 22 April 2020

Type of Action: Research and Innovation (RIA)

Fuente: Comisión Europea.

Call Identifier: SC1-DTH-14-2020

Name: Pre-commercial Procurement for Digital Health and Care Solutions

Scope:

- Proposals should be oriented to support the health and care service provider to procure the development of digital services that can facilitate the transition to integrated care models across health and social services and country-specific cross-institutional set-ups, including decentralized procurement environments and collaboration across institutions.
- The procurers, hospital clusters, care services providers and other parts of the regional ecosystems should share knowledge, test results and needs to better coordinate the primary and community care, and stimulate local responsibility for care services, monitoring and rehabilitation.
- The service innovation should facilitate the early adoption and transferability of successful solutions addressing the innovation gap.

Total Budget: 10 M€

Contribution per project: 5 – 6 M€

Opening date: 19 November 2019

Deadline: 22 April 2020

Type of Action: Pre-Commercial Procurement

Fuente: Comisión Europea.

Prioridad	Topics en esquema Acciones de Coordinación y Apoyo (CSAs)	Mio €	Nº	Mio. €
Contribution to the Call on Digital transformation in Health and Care	SC1-HCC-10-2020[1*]: Towards a Health research and innovation Cloud: Capitalising on data sharing initiatives in health research.	2-3	1	3
Digital Transformation in Health and Care	SC1-HCC-06-2020[2*]: Coordination and Support to better data and secure cross-border digital infrastructures building on European capacities for genomics and personalised medicine.	Up to 4	1	5
	SC1-HCC-07-2020[3*]: Support for European eHealth Interoperability roadmap for deployment.	1,5-2	1	2
	SC1-HCC-08-2020[3*]: Scaling up innovation for active and healthy ageing.	1.5-2	1	2
	SC1-HCC-09-2020[3*]: Supporting deployment of eHealth in low and lower middle income countries in Africa for better health outcomes.	1.5-2	1	2

Fechas de cierre:

[1*]: 07.04.2020

[2*]: 13.11.2019

[3*]: 22.04.2020

Fuente: Comisión Europea.

(III) Trusted digital solutions and cybersecurity in health and care (Topics TDS)

H2020

Horizon Europe

Call Identifier: DT-TDS-04-2020

Name: AI for Genomics and Personalized Medicine

Scope:

- Proposals should demonstrate the potential and benefits of AI technologies for advancing research and personalized medicine through the linking of relevant genomics data and repositories, according to adequate organizational, regulatory, security, ethical and technical requirements.
- Proposals should develop and test AI solutions for linking genomics repositories across the EU, including banks of "-omics" and health related data, biobanks and other registries, with the view of supporting clinical research and decision making.

Expected Impact:

- Effectiveness of AI technologies for genomics and personalized medicine.
- Promoting the sharing of data and infrastructure for personalized medicine through a European network on genomics.

Total Budget: 35 M€

Contribution per project: up to 10 M€

Opening date: 19 November 2019

Deadline: 22 April 2020

Type of Action: Research and Innovation (RIA)

Fuente: Comisión Europea.

Call Identifier: DT-TDS-05-2020

CERRADO

Name: AI for Health Imaging

Scope:

- This action should contribute to testing and developing AI tools and analytics focused on the prevention, prediction and treatment of the most common forms of cancer while providing solutions to securely share health images across Europe.
- Proposals should contribute enabling the development, testing and validation of AI-based health imaging solutions to improve diagnosis, disease prediction and follow-up of the most common forms of cancer.

Expected Impact:

- Contributing towards the creation of a EU-wide repository of health images dedicated to the most common forms of cancer, enabling experimentation of AI-based solutions to get a more precise and personalized management of cancer.

Total Budget: 35 M€

Contribution per project: 8 – 10 M€

Opening date: 9 July 2019

Deadline: 13 November 2019

Type of Action: Research and Innovation (RIA)

Fuente: Comisión Europea.

Call Identifier: DT-ICT-12-2020

Name: AI for the smart hospital of the future

Scope:

- Device in-facility pilot demonstrators that deliver innovative AI-based solutions in a health and care setting such as a hospital, primary care facility or care home. Pilots should enable or support clinical, diagnosis and treatment, etc. carried out with clinical outcomes comparable to human delivered procedures and with comparable results.
- Proposals may address any aspect of health facility operations across their range of functions, such as diagnostics, treatments, logistical aspects, etc.

Expected Impact (a.o.):

- Emergence of European-led AI based pilots for the smart hospital of the future, enabled by open system platforms
- Demonstration of effectiveness, in use, of AI based technologies, such as smart robots, in a range of healthcare tasks
- Engagement of healthcare policy makers, investors, stakeholders and through the pilot.

Total Budget: 40 M€

Contribution per project: 7 – 10 M€

Opening date: 19 November 2019

Deadline: 22 April 2020

Type of Action: Innovation Action (IA)

Fuente: Comisión Europea.

La Iniciativa de Medicamentos Innovadores 2 (IMI2)

http://www.imi.europa.eu/

innovative medicines initiative

Europe's partnership for health

Challenges in clinical development



Fuente: Comisión Europea.

Conceptos clave

- Colaboración público – privada: Comisión Europea – Industria Farmacéutica (EFPIA)
- Desarrollo de la Iniciativa de Medicamentos Innovadores
  - Estructura de gestión
  - Diseño y lanzamiento de convocatorias competitivas
- Necesidad de interdisciplinariedad
  - Compartición de resultados
- Contribución de la industria ‘en especie’

Presupuesto IMI 2 (2014 – 2024)

EU funding goes to:

- Universities
- SMEs
- Mid-sized companies
- Patient groups
- etc…

€1.638 bn

€1.425 bn

EFPIA companies

receive no funding

contribute to projects 'in kind'

Other
€213 m

Associated Partners e.g. charities, non-EFPIA companies

IMI 2 total budget
€3.276 billion

Fuente: Comisión Europea.

Características IMI 2 – Call 20

Call Identifier: H2020-JTI-IMI2 1st stage

Opening date: 21 January

Deadline 1st stage: 21 April 2020

Deadline 2nd stage: 23 June 2020

Global budget: 273, 02 M € (IMIJU + EFPIA contr. + otros)

innovative medicines initiative

Fuente:
https://www.imi.europa.eu/apply-funding/future-topics

Topics en la conv. 20ª de la Iniciativa de Medicamentos Innovadores

1. Early diagnosis, prediction of radiographic outcomes and development of rational, personalised treatment strategies to improve long-term outcomes in Psoriatic Arthritis. Presupuesto: 13,88 M€ (EFPIA) + 10,211 M€ (IMI JU)
2. Innovations to accelerate vaccine development and manufacture. Presupuesto: 19,87 M€ (EFPIA) + 18,6 M€ (IMI JU)
3. Academia and industry united innovation and treatment for tuberculosis (UNITE4TB) Presupuesto: 62,5 M€ (EFPIA) + 92,5 M€ (IMI JU) + 30 M€ (IMI JU Assoc. Partners)
4. Tumour plasticity. Presupuesto: 8,5 M€ (EFPIA) + 7,058 M€ (IMI JU)
5. Proton versus photon therapy for oesophageal cancer – a trimodality strategy. Presupuesto: 1,5 M€ (EFPIA) + 1,5 M€ (IMI JU)
6. Handling of protein drug products and stability concerns. Presupuesto: 3,14 M€ (EFPIA) + 3,96 M€ (IMI JU)

Fuente: IMI2.

Futuras convocatorias (I)

Neurodegeneration and other neuroscience priorities

- Rare neurodegenerative and neurocognitive diseases clinical platform development.
- Complement in neurodegenerative diseases.

'Pain' portfolio

- Digital endpoints and placebo effect in chronic pain.

Infection control including vaccines

- Development of innovative personalized diagnostics and patient-guided therapies for the management of sepsis-induced immune suppression.
- Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance.

Big data, digital health, clinical trials and regulatory research

- Data lakes.
- Personalised endpoints.
- Returning clinical trial data to patients: The proactive return of clinically relevant information to study participants during and after a clinical trial.

Fuente: Comisión Europea.

Futuras convocatorias (II)

Oncology

- Microbiome.
- Real-world clinical implementation of liquid biopsy.

Translational safety

- Pharmacodynamic drug-drug interaction predictive testing by learning algorithms to enhance safety.
- Digital vivarium.

Facilitating rare disease therapies (including Advanced Therapy Medical Products) reaching patients in Europe

- Clinical outcomes assessments for rare diseases.
- Defragmenting and shortening the path to rare disease diagnosis by using genetic screening and digital technologies.

Fuente: Comisión Europea.

Futuras convocatorias (III)

Convocatoria posible en Coronavirus (nCoV-2019) en preparación

- Lanzamiento posible a comienzos de marzo
- *Deadline* posible a finales de marzo
- Una sola fase probablemente
- Título posible de la convocatoria: ***Programme to accelerate development of antiviral agents against nCoV-2019 – basis for a future European R&D rapid response entity for treatments targeting emerging pathogens***
- Evaluación en un periodo de 15 días

Fuente: Comisión Europea.



H2020: Oportunidades de financiación de proyectos de I+i

- Convocatoria 2020 del Reto Social 1
- Convocatoria 20 de la Iniciativa de Medicamentos Innovadores

Consejos prácticos para la redacción de propuestas

Criterios de evaluación

Excellence

Clarity and pertinence of the objectives

Soundness of the concept, including trans-disciplinary considerations, where relevant

Extent that proposed work is ambitious, has innovation potential, and is beyond the state of the art (e.g. ground-breaking objectives, novel concepts and approaches)

Credibility of the proposed approach

Impact

The expected impacts listed in the work programme under the relevant topic

Enhancing innovation capacity and integration of new knowledge

Strengthening the competitiveness and growth of companies by developing innovations meeting the needs of European and global markets; and, where relevant, by delivering such innovations to the markets

Any other environmental and socially important impacts (not already covered above)

Effectiveness of the proposed measures to exploit and disseminate the project results (including management of IPR), to communicate the project, and to manage research data where relevant

Implementation

Coherence and effectiveness of the work plan, including appropriateness of the allocation of tasks and resources

Complementarity of the participants within the consortium (when relevant)

Appropriateness of the management structures and procedures, including risk and innovation management

Convencer al evaluador

- Ilustrar con datos y figuras.
- 5 preguntas básicas a responder:
  - ¿Qué problema concreto se trata de resolver?
  - ¿Tiene relevancia europea? ¿Se podría resolver a nivel nacional?
  - ¿Se encuentra la solución ya disponible (productos, servicios…)?
  - ¿Por qué este proyecto ahora? ¿Qué ocurriría si no se desarrollara ahora?
  - ¿Por qué nosotros? ¿Somos los mejores para realizar el proyecto?

Las respuestas deben ser claras.
El resumen es absolutamente crítico para ello (lectura en 30 segundos).

Seguir instrucciones del documento 'Template'

This template is to be used in a single- stage submission procedure or at the 2nd stage of a two-stage submission procedure.

The structure of this template must be followed when preparing your proposal. It has been designed to ensure that the important aspects of your planned work are presented in a way that will enable the experts to make an effective assessment against the evaluation criteria. Sections 1, 2 and 3 each correspond to an evaluation criterion.

Please be aware that proposals will be evaluated as they were submitted, rather than on their potential if certain changes were to be made. This means that only proposals that successfully address all the required aspects will have a chance of being funded. There will be no possibility for significant changes to content, budget and consortium composition during grant preparation.

⚠ **Page limit**: The title, list of participants and sections 1, 2 and 3, together, should not be longer than 70 pages. All tables, figures, references and any other element pertaining to these sections must be included as an integral part of these sections and are thus counted against this page limit.

The page limit will be applied automatically; therefore you must remove this instruction page before submitting.

If you attempt to upload a proposal longer than the specified limit before the deadline, you will receive an automatic warning and will be advised to shorten and re-upload the proposal. After the deadline, excess pages (in over-long proposals/applications) will be automatically made invisible, and will not be taken into consideration by the experts. The proposal is a self-contained document. Experts will be instructed to ignore hyperlinks to information that is specifically designed to expand the proposal, thus circumventing the page limit.

Please, do not consider the page limit as a target! It is in your interest to keep your text as concise as possible, since experts rarely view unnecessarily long proposals in a positive light.

⚠ The following formatting conditions apply.

The reference font for the body text of H2020 proposals is Times New Roman (Windows platforms), Times/Times New Roman (Apple platforms) or Nimbus Roman No. 9 L (Linux distributions).

The use of a different font for the body text is not advised and is subject to the cumulative conditions that the font is legible and that its use does not significantly shorten the representation of the proposal in number of pages compared to using the reference font (for example with a view to bypass the page limit).

The minimum font size allowed is 11 points. Standard character spacing and a minimum of single line spacing is to be used.

Text elements other than the body text, such as headers, foot/end notes, captions, formula's, may deviate, but must be legible.

The page size is A4, and all margins (top, bottom, left, right) should be at least 15 mm (not including any footers or headers).

Preparando la propuesta

- Analizar el texto del topic muchas veces
- ¿Encaja mi idea “como un guante” / voy a hacerla encajar?
- Convencer
- Nunca dejar la redacción para el último momento
- Revisión del texto por alguien no totalmente experto en el área
- No enviar la propuesta antes de los 5 minutos del cierre de la convocatoria

Claves del éxito: S&T

- Project idea is an excellent fit to the call/topic
- Title & acronym fit the topic addressed
- State of the art: well described & significant advance (beyond)
- Concept & objectives clearly described: real measurable, European value
- Sound methodology to reach objectives:
- Detailed Work plan: WPs well defined, interconnected
- Feasibility of the project, risk identification & contingency plan

Claves del éxito: Impacto

- Cumplir con todos los puntos del apartado “Expected Impact” del topic.
- Otros impactos: científico, técnico, político, social (impacto en salud, económico).
- Impacto real, justificado y convincente.
- Plan de difusión bien ideado y con suficiente detalle.
- Buen Plan de Explotación de los resultados esperados del proyecto: participación de grupos de interés y usuarios finales.
- Los aspectos de PI deben haberse acordado previamente al envío de la propuesta a H2020.

Claves del éxito: Implementación

- Individual participants with outstanding records & expertise
- Consortium suitable of achieving project objectives: balanced (geography, type of organisation), complementarity, multidisciplinar, European dimension
- Management structure / procedures clear & practical to reach objectives
- Experienced coordinator to manage project
- Balanced allocation & good justification of resources (budget, personnel & equipment)



Ejemplo de esquema de gestión



Los aspectos SSH en proyectos H2020

- Aspectos SSH (Social Sciences and Humanities)
- Aspectos de género: sex vs. gender
- Aspectos éticos: confidencialidad, consentimiento, anonimización, uso de animales de experimentación,…
- La difusión vs. comunicación

❑ "Proposals must take account of the social, economic, political, legal, behavioural, institutional, historical and/or cultural dimensions of a given issue, as appropriate and required by the description. A proposal without a sufficient contribution/ integration of SSH research and competences will receive a low evaluation score."

Aspectos de género

The Commission attaches importance to gender equality in research.

- Encourage:

  The project to achieve a good gender balance in their consortium and research team

- Verify research content:

  Fair treatment of women and men, especially important if human beings are involved as research subjects or when consumer/user/patient/client aspects are important

Ética

- El consentimiento informado
- Investigación con embriones humanos
- Justificación del uso de hSC
- Protección de datos y privacidad
- Investigación con animales
- Investigación con terceros países
- Uso dual de los resultados de la I+i

PROTECCIÓN DE DATOS PERSONALES

Basado en el Nuevo

Reglamento Europeo General de Protección de Datos

Regulation (EU) 2016/679

EUROPEAN COMMISSION
Directorate-General for Research & Innovation

Horizon 2020 Programme

Guidance

How to complete your ethics self-assessment

Version 6.1
4 February 2019

Section 4: PROTECTION OF PERSONAL DATA		YES/ NO		Pag.	Information to be provided	Documents to be provided/kept on file
Does your research involve processing of personal data?		☐	☐		1) Details of the technical and organisational measures to safeguard the rights of the research participants) Details of the informed consent procedures. 3) Details of the security measures to prevent unauthorised access to personal data. 4) How is all of the processed data relevant and limited to the purposes of the project ('data minimisation' principle)? Explain. 5) Details of the anonymisation /pseudonymisation techniques. 6) Justification of why research data will not be anonymised/ pseudonymised (if relevant). 7) Details of the data transfers (type of data transferred and country to which it is transferred – for both EU and non-EU countries).	1) Informed Consent Forms + Information Sheets used (if relevant).
If **YES:**	- Does it involve the processing of special categories of personal data (*e.g. genetic, health, sexual lifestyle, ethnicity, political opinion, religious or philosophical conviction*.)?	☐	☐		1) Justification for the processing of special categories of personal data. 2) Why can the research objectives not be reached by processing anonymised/ pseudonymised data (if applicable)?	
	- Does it involve processing of genetic, biometric or health data?	☐	☐			1) Declaration confirming compliance with the laws of the country where the data was collected.
	- Does it involve profiling, systematic monitoring of individuals or processing of large scale of special categories of data, intrusive methods of data processing (*such as, tracking, surveillance, audio and video recording, geo-location tracking etc*.) or any other data processing operation that may result in high risk to the rights and freedoms of the research participants?	☐	☐		1) Details of the methods used for tracking, surveillance or observation of participants. 2) Details of the methods used for profiling. 3) Risk assessment for the data processing activities. 4) How will harm be prevented and the rights of the research participants safeguarded? Explain. 5) Details on the procedures for informing the research participants about profiling, and its possible consequences and the protection measures.	1) Opinion of the data controller on the need for a data protection impact assessment (art.35 GDPR) (if relevant).

Section 4: PROTECTION OF PERSONAL DATA	YES/NO		Pag.	Information to be provided	Documents to be provided/kept on file
Does your research involve further processing of previously collected personal data (*including use of pre-existing data sets or sources, merging existing data sets***)?**	☐	☐		1) Details of the database used or of the source of the data. 2) Details of the data processing operations. 3) How will the rights of the research participants be safeguarded? Explain. 4) How is all of the processed data relevant and limited to the purposes of the project ('data minimisation' principle)? Explain. 5) Justification of why the research data will not be anonymised/ pseudonymised (if relevant).	1) Declaration confirming lawful basis for the data processing. 2) Permission by the owner/manager of the data sets (e.g. social media databases) (if applicable). 3) Informed Consent Forms + Information Sheets + other consent documents (opt in processes, etc.). (if applicable).
Does your research involve publicly available data?	☐	☐		1) Confirm that the data used in the project is publicly available and can be freely used for the project.	1) Permission by the owner/manager of the data sets (e.g. social media databases) (if applicable).
Is it planned to export personal data from the EU to non-EU countries? *Specify the type of personal data and countries involved*	☐	☐		Details of the types of personal data to be exported. How will the rights of the research participants be safeguarded? Explain.	1) Declaration of confirming compliance with Chapter V of the GDPR.
Is it planned to import personal data from non-EU countries into the EU? *Specify the type of personal data and countries involved*	☐	☐		1) Details of the types of personal data to be imported.	1) Declaration confirming compliance with the laws of the country in which the data was collected.

Comunicar y difundir

Mayor importancia de las actividades de comunicación

- Plan de Communication y paquete de trabajo en la propuesta y en el contrato (GA **artículo 38.1**)
- Promocionar el proyecto y sus resultados más allá del propio entorno del proyecto
- Comunicar sobre la investigación llevada a cabo de forma que pueda ser entendida por una audiencia no especializada, por ejemplo, los medios de comunicación y el público en general
- Informar por adelantado a la Comisión Europea o Agencia de aquellas actividades de comunicación de las que se espera un gran impacto

Comunicación ≠ Difusión

Difusión (GA **artículo 29**) es una obligación diferente (ej. artículos científicos o conferencias)

¿En qué se falla más?
Principales puntos de crítica de los evaluadores en propuestas “below available budget”

H2020

Comentarios en relación con el Criterio 1 (Calidad Científico-Técnica) *

• Falta de claridad al redactar (Aspectos de la descripción incompletos o insuficientemente elaborados o no convincentes / base conceptual mal explicada o no convincente)	60 %
• No se describe con claridad el progreso que supone los objetivos de la propuesta más allá del state-of-the-art	11%
• Objetivos poco novedosos	7%
• Poco ambicioso	7%
• Otros (cronograma poco creíble, falta de ajuste al texto del topic, demasiado ambicioso, aspectos éticos no discutidos)	4%

* Porcentaje de comentarios sobre el total para este criterio

Comentarios en relación con el Criterio 2 (Impacto del proyecto) *

• Falta de claridad o incompleto / objetivos de impacto no definidos	27%
• Defectos en el plan de explotación (no se describe o es demasiado amplio, indicadores cuantitativos sin base justificada, el papel de las PYMEs es poco claro)	27%
• Los impactos que se indican no se derivan con claridad de las actividades propuestas o no están bien basados	20%
• Actividades de comunicación / difusión demasiado generales o ambiguos	13%
• La probabilidad de alcanzar el impacto es incierta	7%
• El refuerzo directo del sector comercial europeo que se deriva del proyecto es especulativo	7%
• Otros: no hay análisis o hay sobreestimación del mercado, aspectos de IPR no se han tenido en cuenta, no se analizan las barreras a la innovación	12%

* Porcentaje de comentarios sobre el total para este criterio

Comentarios en relación con el Criterio 3 (La gestión del proyecto) *

• Falta de detalles (descripción de tareas y actividades demasiado sucinta, los lazos entre los diferentes Paquetes de Trabajo y los roles respectivos no se describen bien, falta descripción de socios)	25%
• Plan de contingencias demasiado general, medidas para mitigar riesgos no convincentes	21%
• Cronograma poco claro (la distribución de hitos no encaja bien, tiempos similares para todos los Paquetes de Trabajo, tiempos demasiado cortos)	12%
• Fallos en el presupuesto (recursos insuficientes en relación con las tareas propuestas, desequilibrio, falta de justificación en partidas muy elevadas)	8%
• Enfoque técnico inadecuado o no se apoya en datos preliminares	6%
• El plan de gestión no incluye innovación y comunicación (no se incluye un gestor/a de la innovación)	4%
• No se dedica tiempo suficiente a la gestión de la calidad	4%

* Porcentaje de comentarios sobre el total para este criterio

Ser evaluador: un modo de aprender



https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/work-as-an-expert

GOBIERNO DE ESPAÑA
MINISTERIO DE CIENCIA E INNOVACIÓN
Instituto de Salud Carlos III

¡Muchas gracias por su atención!



Juan E. Riese
jriese@eu-isciii.es
+34 91 822 21 81

Información sobre convocatorias en: http://eu-isciii.es